Market Movers Today: Aemetis Inc (AMTX), Ciena Corporation (CIEN), Baytex Energy Corp (BTE), Marinus Pharmaceuticals Inc (MRNS), and More

Baytex Energy Corp (NYSE:BTE) (The Motley Fool)
In previous articles, I have discussed how Baytex Energy Corp.’s (TSX:BTE)(NYSE:BTE) stock is trading below 2016 levels, despite the fact that oil has increased approximately 60% since then, and how this disconnect represents an opportunity. Well, today’s better-than-expected fourth-quarter and year-end 2017 results should go a long way in rectifying this. Baytex reported adjusted funds flow of $0.45 per share — an increase of 37%. This was driven by a 7% production increase compared to last year and higher prices. Baytex’s realized prices for its heavy and light oil production increased more than 20%, driving these results and giving Baytex the cash flow it so desperately needed.

GlycoMimetics Inc (NASDAQ:GLYC) (Benzinga)
GlycoMimetics Inc dropped 20 percent to $18.26 after reporting the design of phase 3 trial of GMI-1271 in relapsed/refractory AML. GlycoMimetics reported a Q4 loss of $0.27 per share.

Square Inc (NYSE:SQ) (MarketWatch)
Shares of Square Inc. SQ, -1.57% are down 4.5% in Tuesday morning trading, after closing at an all-time high in the prior session. Analysts remain bullish on the stock, including Instinet’s Dan Dolev, who reiterated his optimism for Square in a Tuesday note. He argued that gross payment volume could accelerate in 2018 and that a recent deceleration in Square Capital loan volumes shouldn’t be cause for concern. Dolev is upbeat about the fact that most large sellers are onboarding themselves to the platform. He has a buy rating on the stock and a $64 price target, the highest among all analysts, according to FactSet.

Mylan NV (NASDAQ:MYL) (TheStreet)
Shares of Mylan NV (MYL) surged on Tuesday, March 6, after Morgan Stanley & Co. LLC upgraded its rating on the stock and said the drugmaker is “well positioned” to gain share in the U.S. generics market. The stock jumped 5% to $43.66 in morning trading. Shares are up 3% year-to-date but down 1% over the last 12 months. Morgan Stanley analyst David Risinger hiked his rating on Mylan to overweight from equal-weight and increased his price target from $39 to $50, citing greater confidence in the company’s growth prospects. “Beyond its strong pipeline of new products, Mylan has opportunities to gain share relative to generic competitors which are facing challenges,” Risinger said in the note.

Amedica Corporation (NASDAQ:AMDA) (Benzinga)
Amedica Corporation shares climbed 34.5 percent to $2.69 after the company reported the FDA clearance of Valeo C+CsC with Lumen Interbody Fusion Device.